Nonhypercalcemic 1,25-(OH)2D3 analogs potently induce the human osteocalcin gene promoter stably transfected into rat osteosarcoma cells (ROSCO-2)
Open Access
- 1 August 1991
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 6 (8) , 893-899
- https://doi.org/10.1002/jbmr.5650060815
Abstract
1,25-Dihydroxyvitamin D3[1,25-(OH)2D3] is the active hormonal form of vitamin D3 and has potent effects on bone and calcium regulation. Over the past decade it has become apparent that 1,25-(OH)2D3 has other effects on cellular proliferation that potentially could be developed for therapy in human malignancy. Since the hypercalcemic effects of 1,25-(OH)2D3 have limited that use in the human, novel nonhypercalcemic analogs of 1,25-(OH)2D3 have been synthesized. The molecular mechanism of this divergence in these antiproliferative and calcium-regulating actions is unexplained. We have previously examined the human bone-specific gene osteocalcin as a model of the molecular mechanisms of vitamin D action in bone and have shown that induction of the osteocalcin gene by 1,25-(OH)2D3 is mediated through an unique and complex palindromic region of the promoter similar to but distinct from those of other steroid hormone-responsive elements. Using an osteosarcoma cell line permanently transfected with the vitamin D-responsive promoter of the human osteocalcin gene linked to a “reporter” gene, we have shown that there is a dose-dependent induction of CAT activity by 1,25-(OH)2D3 and that the potencies of vitamin D metabolites and analogs are comparable to those found in other vitamin D bioassays. Furthermore, vitamin D analogs, including MC-903, 22-oxa-1,25-(OH)2D3, and Δ22–1,25S,26-trihydroxyvitamin D3, which effect cellular differentiation but lack hypercalcemic activity in vivo, exhibit osteocalcin promoter inductive actions virtually identical to those of 1,25-(OH)2D3. Consideration of these and other data support the hypothesis that the divergent effects of such analogs on differentiation and calcium homeostasis reflect pharmacokinetic differences in vivo rather than distinct 1,25-(OH)2D3-sensitive pathways.Keywords
Funding Information
- National Health and Medical Research Council
This publication has 35 references indexed in Scilit:
- Improvement of psoriasis by a topical vitamin D3 analogue (MC 903) in a double-blind studyBritish Journal of Dermatology, 1988
- The synthesis and biological activity of 25-hydroxy-26,27-dimethylvitamin D3 and 1,25-dihydroxy-26,27-dimethylvitamin D3: highly potent novel analogs of vitamin D3The Journal of Steroid Biochemistry and Molecular Biology, 1988
- Human colon cell line HT-29: Characterisation of 1,25-dihydroxyvitamin D3 receptor and induction of differentiation by the hormoneThe Journal of Steroid Biochemistry and Molecular Biology, 1988
- Biochemical significance of enhanced activity of fluorinated 1,25‐dihydroxyvitamin D3 in human cultured cell linesCell Biochemistry and Function, 1986
- 1 alpha,25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells.Journal of Clinical Investigation, 1984
- 1,25-Dihydroxyvitamin D3 inhibits selectively the mitogenic stimulation of mouse medullary thymocytesBiochemical and Biophysical Research Communications, 1984
- 1α,25-Dihydroxyvitamin D3 induces differentiation of human myeloid leukemia cellsBiochemical and Biophysical Research Communications, 1981
- 1,25-dihydroxyvitamin D3 specifically binds to a human breast cancer cell line (T47D) and stimulates growthBiochemical and Biophysical Research Communications, 1981
- 1,25-DIHYDROXYVITAMIN D3AND MALIGNANT MELANOMA: THE PRESENCE OF RECEPTORS AND INHIBITION OF CELL GROWTH IN CULTUREEndocrinology, 1981
- 1,25-dihydroxyvitamin D3 receptor in a cultured human breast cancer cell line (MCF 7 cells)Biochemical and Biophysical Research Communications, 1980